Jacqueline A Shaw, Karen Page, Evie Wren, Elza C de Bruin, Ekaterina Kalashnikova, Robert Hastings, Rob McEwen, Eddie Zhang, Marc Wadsley, Emmanuel Acheampong, Derek Renner, Kelly L T Gleason, Bana Ambasager, Daniel Stetson, Daniel Fernandez-Garcia, David Guttery, Rebecca C Allsopp, Angel Rodriguez, Bernhard Zimmermann, Himanshu Sethi, Alexey Aleshin, Minetta C Liu, Cathy Richards, Justin Stebbing, Simak Ali, Farah Rehman, Susan Cleator, Laura Kenny, Samreen Ahmed, Anne C Armstrong, R Charles Coombes
PURPOSE: Here, we report the sensitivity of a personalized, tumor-informed circulating tumor DNA (ctDNA) assay (Signatera) for detection of molecular relapse during long-term follow-up of patients with breast cancer. METHODS: A total of 156 patients with primary breast cancer were monitored clinically for up to 12 years after surgery and adjuvant chemotherapy. Semiannual blood samples were prospectively collected, and analyzed retrospectively to detect residual disease by ultradeep sequencing using ctDNA assays, developed from primary tumor whole-exome sequencing data...
April 2024: JCO Precision Oncology